November 04, 2025

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

Conexiant

October 30, 2025

Viral Infections Increase Cardiovascular Disease Risk 

Systematic review identifies influenza, COVID-19, HIV, hepatitis C, and herpes zoster as significant cardiac risk factors in analysis of 155 studies.

Conexiant

October 29, 2025

Could the Way You Walk Change Outcomes?

Researchers find that the duration of walking bouts—not just total daily steps—predicts long-term cardiovascular and mortality risk.

Conexiant

October 27, 2025

How Hormones May Influence Tirzepatide Outcomes

Researchers show how reproductive stage and hormone therapy influence weight-loss outcomes in women treated with tirzepatide.

Conexiant

October 24, 2025

A New Approach to Lowering Cardiovascular Risk?

Researchers evaluated obicetrapib’s effects on lipid levels and cardiovascular outcomes.

Conexiant

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 21, 2025

Child Weight and NHS Costs: The New Data

Cost variations emerged across age groups and ethnicities, with girls showing higher expenses for severe obesity than boys.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant